Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC Directories Mobile Apps Celebrity VCs VentureTrackr Archive About Us
VC-funded Company:

1337 3rd Avenue
San Francisco, CA 94122
Phone: 415-505-0809

Satsuma Pharmaceuticals' lead product candidate is STS101, a potential best-in-class therapy for migraine that combines the gold-standard anti-migraine drug, dihydroergotamine (DHE), with unique and proprietary dry-powder nasal formulation and delivery technologies created and developed over the past 15 years by SNBL that enable rapid absorption with high bioavailability of drugs delivered via the nose. DHE has multiple therapeutic advantages over other migraine therapies, including triptan therapies, but is not currently available in a fast-acting, patient-friendly, non-injectable preparation that achieves a pharmacokinetic profile similar to that achieved with injection.

Key Contact

Funding Events
01/09/17$12,000,000Series A RA Capital Management
TPG Biotech
Massinvestor/VC News Daily

© 2017 Massinvestor, Inc.